TriSalus Life Sciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from TriSalus Life Sciences, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-59.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 75% of Healthcare companies in United States.
Cash Locked Ratio
$14For every $100 of sales, $14 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $15 from others' credit three years earlier.
Less money tied up than 70% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$24Sales grew 264% in 3 years; of every extra $100 of sales, $24 became extra profit.
Higher than 55% of Healthcare companies in United States.
Asset Productivity Ratio
+264% / +61%In 3 years sales changed by +264% while total assets changed by +61%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-107.9×Operating cash was negative last year, while some debt falls due within a year.
Lower than 84% of Healthcare companies in United States.
Cash Cushion Ratio
−6%Debt, after subtracting cash, equals 6% of its market value (net debt).
Lower than 76% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
TriSalus Life Sciences, Inc. made a loss over the last year. TriSalus Life Sciences, Inc. owes $0.90 for every $1 it owns. TriSalus Life Sciences, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossTriSalus Life Sciences, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
34.41The share price is 34.41 times TriSalus Life Sciences, Inc.'s book value per share, higher than 97% of Healthcare companies in United States.
Market cap
$225 MThe total market value of all of TriSalus Life Sciences, Inc.'s shares at today's price (share price × number of shares), smaller than 57% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$7 MWhat TriSalus Life Sciences, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.11Net worth divided by the number of shares. The share price of $3.66 is 34.4 times this, which is the P/B above.
Owes vs Owns
0.90×TriSalus Life Sciences, Inc. owes $0.90 for every $1 it owns (high), higher than 83% of Healthcare companies in United States.
Dividend yield
NoneTriSalus Life Sciences, Inc. does not currently pay a dividend.
Revenue growth
+53%Revenue rose 53% in the year to Dec 2025, and grew 54% a year on average over 3 years.
Profit growth
LossTriSalus Life Sciences, Inc. made a loss in each of the last two years.
Profit margin
-86.9%TriSalus Life Sciences, Inc. lost $87 for every $100 of revenue.
Interest cover
Not coveredTriSalus Life Sciences, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtTriSalus Life Sciences, Inc. had $14 M more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For TriSalus Life Sciences, Inc.: $225 M ÷ $7 M (30 Jun 2026) = 34.4.
How much does TriSalus Life Sciences, Inc. owe compared with what it owns?
TriSalus Life Sciences, Inc. owes $0.90 for every $1 it owns (high), higher than 83% of Healthcare companies in United States.
Does TriSalus Life Sciences, Inc. pay a dividend?
No. TriSalus Life Sciences, Inc. does not currently pay a dividend.
Is TriSalus Life Sciences, Inc.'s revenue growing?
Revenue rose 53% in the year to Dec 2025, and grew 54% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.